Spyre Therapeutics
SYRE
Spyre Therapeutics (SYRE) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Buy | $120.00 | Oct 12, 2026 |
| BTIG | Maintained | Buy | $121.00 | Oct 1, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $110.00 | Oct 1, 2026 |
| Wedbush | Maintained | Outperform | $123.00 | Sep 9, 2026 |
| BTIG | Maintained | Buy | $121.00 | Sep 8, 2026 |
| BTIG | Maintained | Buy | $121.00 from $132.00 | Aug 26, 2026 |
| Wedbush | Maintained | Outperform | $123.00 from $130.00 | Aug 26, 2026 |
| Deutsche Bank | Maintained | Buy | $127.00 from $135.00 | Aug 26, 2026 |
| BTIG | Maintained | Buy | $132.00 from $112.00 | Aug 11, 2026 |
| Wedbush | Maintained | Outperform | $130.00 from $100.00 | Aug 5, 2026 |
| Guggenheim | Maintained | Buy | $130.00 from $115.00 | Aug 5, 2026 |
| Wells Fargo | Maintained | Overweight | $115.00 from $90.00 | Aug 5, 2026 |
| Wolfe Research | Downgraded | Outperform → Peer Perform | — | Jul 28, 2026 |
| Mizuho | Maintained | Outperform | $120.00 from $84.00 | Jul 13, 2026 |
| Deutsche Bank | Maintained | Buy | $135.00 from $115.00 | Jun 23, 2026 |
| BTIG | Maintained | Buy | $112.00 from $98.00 | Jun 15, 2026 |
| Deutsche Bank | Maintained | Buy | $115.00 from $102.00 | Jun 4, 2026 |
| Stifel | Maintained | Buy | $107.00 from $92.00 | May 6, 2026 |
| Citigroup | Maintained | Buy | $97.00 from $64.00 | May 6, 2026 |
| Jones Trading | Maintained | Buy | $95.00 from $64.00 | Apr 17, 2026 |
Frequently asked questions
What is the latest analyst rating on SYRE?
On Oct 12, 2026, UBS initiated coverage of Spyre Therapeutics at Buy with a price target of $120.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.